• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Characterization of METRNβ as a novel biomarker of Coronavirus disease 2019 severity and prognosis

tetano

Editor, Senior Moderator
Front Immunol


. 2023 Jan 31;14:1111920.
doi: 10.3389/fimmu.2023.1111920. eCollection 2023.
Characterization of METRNβ as a novel biomarker of Coronavirus disease 2019 severity and prognosis


Xun Gao[SUP] 1 2 [/SUP], Paul Kay-Sheung Chan[SUP] 3 4 [/SUP], Katie Ching-Yau Wong[SUP] 2 [/SUP], Rita Wai-Yin Ng[SUP] 3 [/SUP], Apple Chung-Man Yeung[SUP] 3 [/SUP], Grace Chung-Yan Lui[SUP] 4 5 [/SUP], Lowell Ling[SUP] 6 [/SUP], David Shu-Cheong Hui[SUP] 4 5 [/SUP], Danqi Huang[SUP] 2 [/SUP], Chun-Kwok Wong[SUP] 2 7 8 [/SUP]



Affiliations

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) is increasing worldwide, with complications due to frequent viral mutations, an intricate pathophysiology, and variable host immune responses. Biomarkers with predictive and prognostic value are crucial but lacking.
Methods: Serum samples from authentic and D614G variant (non-Omicron), and Omicron-SARS-CoV-2 infected patients were collected for METRNβ detection and longitudinal cytokine/chemokine analysis. Correlation analyses were performed to compare the relationships between serum METRNβ levels and cytokines/chemokines, laboratory parameters, and disease severity. Receiver operating characteristic (ROC) curves and Kaplan-Meier survival curves were used to evaluate the predictive value of METRNβ in COVID-19.
Results: The serum level of METRNβ was highly elevated in non-Omicron-SARS-CoV-2 infected patients compared to healthy individuals, and the non-survivor displayed higher METRNβ levels than survivors among the critical ones. METRNβ concentration showed positive correlation with viral load in NAPS. ROC curve showed that a baseline METRNβ level of 1886.89 pg/ml distinguished COVID-19 patients from non-infected individuals with an AUC of 0.830. Longitudinal analysis of cytokine/chemokine profiles revealed a positive correlation between METRNβ and pro-inflammatory cytokines such as IL6, and an inverse correlation with soluble CD40L (sCD40L). Higher METRNβ was associated with increased mortality. These findings were validated in a second and third cohort of COVID-19 patients identified in a subsequent wave.
Discussion: Our study uncovered the precise role of METRNβ in predicting the severity of COVID-19, thus providing a scientific basis for further evaluation of the role of METRNβ in triage therapeutic strategies.

Keywords: COVID-19; METRNβ; biomarker; cytokines; prognostic.
 
Back
Top Bottom